CD7 (CD7 Molecule)

The positive expression rate of CD7 is relatively high in ENKTL patients. CD7 positive is an independent risk factor affecting patients' survival, and patients with CD7 positive have shorter survival periods.

P1/2, N=0, Withdrawn, Guangzhou Bio-gene Technology Co., Ltd | N=30 --> 0 | Active, not recruiting --> Withdrawn

P=N/A, N=12, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

High frequencies of PD-L1+memory B cells, PD-1+DC and PD-1+naïve CD4+ T cells correlated with shorter progression-free survival, whereas normal levels of PD-1+transitional monocytes were associated with longer overall survival. Lesion-specific aberrant T cells and TME remodeling may drive MF severity and contribute to future immunotherapy.

AML harbouring KMT2A-PTD frequently displays MR immunophenotypic abnormalities and is frequently associated with AML-MR type mutations. In addition, they have similar outcomes as compared with AML-MR.

Antigenic shifts affecting megakaryocytic, myeloid, progenitor-associated, and lymphoid markers are common after chemotherapy. For MRD assessment, the use of more specific megakaryocytic markers such as CD110, together with comprehensive multiparameter flow cytometry panels, may improve detection accuracy.

Additionally, the clinical use of tyrosine kinase inhibitors in some of these cases showed therapeutic efficacy. Collectively, these findings identify BCL11B-enhancer mediated deregulation of FOXF1/FENDRR as a hallmark of a subtype of high-risk lineage ambiguous leukemia that is potentially amenable to targeted therapeutic intervention.

We report a case of a 60-year-old man with multi-refractory T-LBL exhibiting a partial response to hyper-CVAD followed by progression on venetoclax plus azacitidine. This patient achieved complete remission after a single cycle of DMPD salvage therapy comprising daratumumab, liposomal mitoxantrone, pegaspargase and dexamethasone...It successfully bridged the patient to double umbilical cord blood transplantation, resulting in full donor chimerism by day +21 and sustained remission despite post-transplant complications. The remarkable efficacy observed in this refractory T-LBL case, contrasting sharply with historical treatment outcomes, suggests that the DMPD regimen may serve as both an immediately actionable and potentially definitive therapeutic approach for elderly patients who are ineligible for hematopoietic stem cell transplantation.

P2, N=97, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027

P1, N=27, Not yet recruiting, Baylor College of Medicine | Initiation date: Dec 2025 --> Jun 2026

Persistent, progressive, or therapy-resistant oral ulcerations should prompt early consideration of hematologic malignancy. Timely biopsy with comprehensive immunophenotyping, EBV testing, and close multidisciplinary collaboration are essential for accurate diagnosis and may contribute to earlier diagnosis and improved patient outcomes in these rare and atypical presentations.

Incorporation of EGFRt in the CAR construct allowed elimination by cetuximab in case of adverse events, whereas inclusion of c-Jun in the construct reduced functional exhaustion after repeated tumor challenges in vitro...This cell subset exhibited broad activation of the Src/Ras/ERK and Bcl-2 pathways, high levels of SOS1 and KLF2 expression, and specific ligand-receptor interactions within the tumor necrosis factor superfamily. Collectively, these results suggest that further clinical development of CCR4/CD7 bispecific CD7N CAR-T cells is warranted, including the AQP3+ subset with SOS1/KLF2 modulation.